International Journal of Antimicrobial Agents
Volume 31, Issue 4 , Pages 329-336 , April 2008

In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures

  • Marie Tré-Hardy

      Affiliations

    • Pharmaceutical Microbiology Laboratory, Institute of Pharmacy, Université Libre de Bruxelles, CP 205/02, Boulevard du Triomphe, 1050 Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 2 650 5290; fax: +32 2 650 5305.
    • ,
  • Francis Vanderbist

      Affiliations

    • Laboratories SMB, 26–28 rue de la Pastorale, 1080 Brussels, Belgium
    • ,
  • Hamidou Traore

      Affiliations

    • Laboratories SMB, 26–28 rue de la Pastorale, 1080 Brussels, Belgium
    • ,
  • Michel Jean Devleeschouwer

      Affiliations

    • Pharmaceutical Microbiology Laboratory, Institute of Pharmacy, Université Libre de Bruxelles, CP 205/02, Boulevard du Triomphe, 1050 Brussels, Belgium
    • Environmental Microbiology Unit, School of Public Health, Université Libre de Bruxelles, 808 route de Lennik, 1070 Brussels, Belgium

Received 8 November 2007 ,Accepted 6 December 2007.

References 

  1. Jaffè A. The anti-inflammatory effects of macrolides in cystic fibrosis. Jpn J Antibiot. 2001;54(Suppl. A):77–82
  2. Muanprasat C, Kaewmokul S, Chatsudthipong V. Identification of new small molecule inhibitors of cystic fibrosis transmembrane conductance regulator protein: in vitro and in vivo studies. Biol Pharm Bull. 2007;30:502–507
  3. Livraghi A, Randell SH. Cystic fibrosis and other respiratory diseases of impaired mucus clearance. Toxicol Pathol. 2007;35:116–129
  4. Chen X, Schauder S, Potier N, Van Dorsselaer A, Pelczer I, Bassler BL, et al. Structural identification of a bacterial quorum-sensing signal containing boron. Nature. 2002;415:545–549
  5. Rejman J, Di Gioia S, Bragonzi A, Conese M. Pseudomonas aeruginosa infection destroys the barrier function of lung epithelium and enhances polyplex-mediated transfection. Hum Gene Ther. 2007;18:642–652
  6. Hoiby N, Koch C. Cystic fibrosis 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax. 1990;45:881–884
  7. Lenoir G. Pseudomonas aeruginosa and mucoviscidosis. Rev Pneumol Clin. 1995;51:151–159[in French]
  8. Staab D. Cystic fibrosis—therapeutic challenge in cystic fibrosis children. Eur J Endocrinol. 2004;151(Suppl. 1):S77–S80
  9. May TB, Shinabarger D, Maharaj R, Kato J, Chu L, DeVault JD, et al. Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin Microbiol Rev. 1991;4:191–206
  10. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol. 2007;42:307–313
  11. Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, O’Toole GA. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature. 2003;426:306–310
  12. Giamarellos-Bourboulis EJ, Antonopoulou A, Raftogiannis M, Koutoukas P, Tsaganos T, Tziortzioti V, et al. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa. BMC Infect Dis. 2006;6:31
  13. Shinkai M, Lopez-Boado YS, Rubin BK. Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin. J Antimicrob Chemother. 2007;59:1096–1101
  14. Kandemir O, Oztuna V, Milcan A, Bayramoglu A, Celik HH, Bayarslan C, et al. Clarithromycin destroys biofilms and enhances bactericidal agents in the treatment of Pseudomonas aeruginosa osteomyelitis. Clin Orthop Relat Res. 2005;430:171–175
  15. Abdi-Ali A, Mohammadi-Mehr M, Agha Alaei Y. Bactericidal activity of various antibiotics against biofilm-producing Pseudomonas aeruginosa. Int J Antimicrob Agents. 2006;27:196–200
  16. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999;37:1771–1776
  17. Kondoh K, Hashiba M, Baba S. Inhibitory activity of clarithromycin on biofilm synthesis with Pseudomonas aeruginosa. Acta Otolaryngol Suppl. 1996;525:56–60
  18. Nagata T, Mukae H, Kadota J, Hayashi T, Fujii T, Kuroki M, et al. Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. Antimicrob Agents Chemother. 2004;48:2251–2259
  19. Falagas ME, Kasiakou SK. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis. Infection. 2007;35:3–10
  20. Hancock RE, Bell A. Antibiotic uptake into Gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 1988;7:713–720
  21. Nicas TI, Hancock RE. Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediaminetetraacetate, polymyxin B, and gentamicin. J Bacteriol. 1980;143:872–878
  22. Mor N, Heifets L. MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages. Antimicrob Agents Chemother. 1993;37:111–114
  23. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th ed. Approved standard. M7-A6. Wayne, PA: CLSI; 2003.
  24. Balke B, Hogardt M, Schmoldt S, Hoy L, Weissbrodt H, Haussler S. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis. 2006;25:25–30
  25. Mackay ML, Milne K, Gould IM. Comparison of methods for assessing synergic antibiotic interactions. Int J Antimicrob Agents. 2000;15:125–129
  26. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52:1
  27. Gordon CA, Hodges NA, Marriott C. Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosis-derived Pseudomonas aeruginosa. J Antimicrob Chemother. 1988;22:667–674
  28. Cystic Fibrosis Inhaled Tobramycin Study GroupRamsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340:23–30
  29. British Society for Antimicrobial Chemotherapy . Determination of minimum inhibitory concentrations. Guide to antimicrobial susceptibility testing. Birmingham, UK: BSAC; 2006;p. 19
  30. Aaron SD, Ferris W, Ramotar K, Vandemheen K, Chan F, Saginur R. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J Clin Microbiol. 2002;40:4172–4179
  31. Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med. 1995;99:26S–30S
  32. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med. 1997;155:2018–2023
  33. Anwar H, Costerton JW. Enhanced activity of combination of tobramycin and piperacillin for eradication of sessile biofilm cells of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1990;34:1666–1671
  34. Eckert R, Brady KM, Greenberg EP, Qi F, Yarbrough DK, He J, et al. Enhancement of antimicrobial activity against Pseudomonas aeruginosa by coadministration of G10KHc and tobramycin. Antimicrob Agents Chemother. 2006;50:3833–3838
  35. Tanaka G, Shigeta M, Komatsuzawa H, Sugai M, Suginaka H, Usui T. Effect of clarithromycin on Pseudomonas aeruginosa biofilms. Chemotherapy. 2000;46:36–42
  36. Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother. 2002;46:1105–1107
  37. Yasuda H, Ajiki Y, Koga T, Kawada H, Yokota T. Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. Antimicrob Agents Chemother. 1993;37:1749–1755
  38. Ichimiya T, Yamasaki T, Nasu M. In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation. J Antimicrob Chemother. 1994;34:331–341
  39. Tamaoki J, Isono K, Sakai N, Kanemura T, Konno K. Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur Respir J. 1992;5:234–238
  40. Guillot M, Eckart P, Desrosieres H, Brouard J. Macrolides and Pseudomonas aeruginosa infection. Arch Pediatr. 2000;7(Suppl. 3):523s–530s[in French]
  41. Howe RA, Spencer RC. Macrolides for the treatment of Pseudomonas aeruginosa infections?. J Antimicrob Chemother. 1997;40:153–155
  42. Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother. 2004;54:21–28
  43. Takeoka K, Ichimiya T, Yamasaki T, Nasu M. The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm. Chemotherapy. 1998;44:190–197
  44. Bui KQ, Banevicius MA, Nightingale CH, Quintiliani R, Nicolau DP. In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa. J Antimicrob Chemother. 2000;45:57–62
  45. Yanagihara K, Tomono K, Sawai T, Kuroki M, Kaneko Y, Ohno , et al. Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation. J Antimicrob Chemother. 2000;46:69–72

PII: S0924-8579(08)00013-7

doi: 10.1016/j.ijantimicag.2007.12.005

International Journal of Antimicrobial Agents
Volume 31, Issue 4 , Pages 329-336 , April 2008

Article Tools

* Image Usage & Resolution